Loading…
Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells
We developed three daunorubicin (D1)-resistant sublines (ML1/I, II, III) from the human myelocytic cell line (ML1). These sublines were 28-, 70- and 162-fold more resistant than sensitive (ML1/S) cells to the cytotoxicity of D1 and were cross-resistant to adriamycin, epiadriamycin, actinomycin D, VP...
Saved in:
Published in: | Cancer chemotherapy and pharmacology 1986-01, Vol.18 (2), p.105-110 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c311t-d7f7a063511b0d3073cd07305ba3ed110cf5caea71da18348a017807ab0953b03 |
---|---|
cites | |
container_end_page | 110 |
container_issue | 2 |
container_start_page | 105 |
container_title | Cancer chemotherapy and pharmacology |
container_volume | 18 |
creator | VASANTHAKUMAR, G AHMED, N. K |
description | We developed three daunorubicin (D1)-resistant sublines (ML1/I, II, III) from the human myelocytic cell line (ML1). These sublines were 28-, 70- and 162-fold more resistant than sensitive (ML1/S) cells to the cytotoxicity of D1 and were cross-resistant to adriamycin, epiadriamycin, actinomycin D, VP-16, VM26, and mitoxantrone. Steady-state levels of D1 in resistant sublines I and II, in the presence or absence of azide, were not significantly different from those of sensitive cells. However, the steady-state level of D1 in subline III was significantly increased in the presence of sodium azide. D1 efflux was minimal in ML1/S and resistant cells in the absenced of glucose. Addition of glucose enhanced D1 efflux only in subline III. Verapamil increased the cellular levels of D1 and inhibited its efflux from resistant III cells but not from ML1/S cells. Verapamil also greatly enhanced the cytotoxicity of D1 for sublines I, II, and III. The differences between sensitive and resistant cells in D1 uptake and retention seemed inadequate to cause 162-fold resistance and suggested other factors may be contributing to the development of resistance. In support of this hypothesis, daunorubicin reductase activity was significantly lower in resistant cells than in ML1/S cells. The greatest decrease in activity occurred at pH 8.5 which represents aldehyde reductases. Currently, we are investigating other possibilities for D1 metabolism, such as aglycone and free radical formation. |
doi_str_mv | 10.1007/BF00262277 |
format | article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00262277</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3539383</sourcerecordid><originalsourceid>FETCH-LOGICAL-c311t-d7f7a063511b0d3073cd07305ba3ed110cf5caea71da18348a017807ab0953b03</originalsourceid><addsrcrecordid>eNpFkE1Lw0AQhhdRaq1evAt78CREZzNJNzlqsSoUvOg5zH5EV5Js2d0c-u-NtNTLvAzvwww8jF0LuBcA8uFpDZAv81zKEzYXBeYZVAWesjlgUWSlhOKcXcT4AwCFQJyxGZZYY4VzplZ-SMGpMTk_cN9yE8YvngINcetD4jQYHqwZdaJoI0-eGxoHH0bltBumKrqYaNCWT9v32NPA-53tvN4lp7m2XRcv2VlLXbRXh1ywz_Xzx-o127y_vK0eN5lGIVJmZCsJllgKocAgSNRmGlAqQmuEAN2WmixJYUhUWFQEQlYgSUFdogJcsLv9XR18jMG2zTa4nsKuEdD8eWr-PU3wzR7ejqq35ogexEz97aGnqKlrJyHaxSMm63o5vcdfIKZwYQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells</title><source>Springer Online Journal Archives (Through 1996)</source><creator>VASANTHAKUMAR, G ; AHMED, N. K</creator><creatorcontrib>VASANTHAKUMAR, G ; AHMED, N. K</creatorcontrib><description>We developed three daunorubicin (D1)-resistant sublines (ML1/I, II, III) from the human myelocytic cell line (ML1). These sublines were 28-, 70- and 162-fold more resistant than sensitive (ML1/S) cells to the cytotoxicity of D1 and were cross-resistant to adriamycin, epiadriamycin, actinomycin D, VP-16, VM26, and mitoxantrone. Steady-state levels of D1 in resistant sublines I and II, in the presence or absence of azide, were not significantly different from those of sensitive cells. However, the steady-state level of D1 in subline III was significantly increased in the presence of sodium azide. D1 efflux was minimal in ML1/S and resistant cells in the absenced of glucose. Addition of glucose enhanced D1 efflux only in subline III. Verapamil increased the cellular levels of D1 and inhibited its efflux from resistant III cells but not from ML1/S cells. Verapamil also greatly enhanced the cytotoxicity of D1 for sublines I, II, and III. The differences between sensitive and resistant cells in D1 uptake and retention seemed inadequate to cause 162-fold resistance and suggested other factors may be contributing to the development of resistance. In support of this hypothesis, daunorubicin reductase activity was significantly lower in resistant cells than in ML1/S cells. The greatest decrease in activity occurred at pH 8.5 which represents aldehyde reductases. Currently, we are investigating other possibilities for D1 metabolism, such as aglycone and free radical formation.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/BF00262277</identifier><identifier>PMID: 3539383</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Alcohol Oxidoreductases - analysis ; Aldehyde Reductase ; Aldo-Keto Reductases ; Antineoplastic agents ; Biological and medical sciences ; Biological Transport ; Cell Line ; Daunorubicin - metabolism ; Daunorubicin - pharmacology ; Drug Resistance ; Drug Synergism ; General aspects ; Humans ; Leukemia, Myeloid - metabolism ; Medical sciences ; Pharmacology. Drug treatments ; Verapamil - pharmacology</subject><ispartof>Cancer chemotherapy and pharmacology, 1986-01, Vol.18 (2), p.105-110</ispartof><rights>1987 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c311t-d7f7a063511b0d3073cd07305ba3ed110cf5caea71da18348a017807ab0953b03</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=7996017$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3539383$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VASANTHAKUMAR, G</creatorcontrib><creatorcontrib>AHMED, N. K</creatorcontrib><title>Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>We developed three daunorubicin (D1)-resistant sublines (ML1/I, II, III) from the human myelocytic cell line (ML1). These sublines were 28-, 70- and 162-fold more resistant than sensitive (ML1/S) cells to the cytotoxicity of D1 and were cross-resistant to adriamycin, epiadriamycin, actinomycin D, VP-16, VM26, and mitoxantrone. Steady-state levels of D1 in resistant sublines I and II, in the presence or absence of azide, were not significantly different from those of sensitive cells. However, the steady-state level of D1 in subline III was significantly increased in the presence of sodium azide. D1 efflux was minimal in ML1/S and resistant cells in the absenced of glucose. Addition of glucose enhanced D1 efflux only in subline III. Verapamil increased the cellular levels of D1 and inhibited its efflux from resistant III cells but not from ML1/S cells. Verapamil also greatly enhanced the cytotoxicity of D1 for sublines I, II, and III. The differences between sensitive and resistant cells in D1 uptake and retention seemed inadequate to cause 162-fold resistance and suggested other factors may be contributing to the development of resistance. In support of this hypothesis, daunorubicin reductase activity was significantly lower in resistant cells than in ML1/S cells. The greatest decrease in activity occurred at pH 8.5 which represents aldehyde reductases. Currently, we are investigating other possibilities for D1 metabolism, such as aglycone and free radical formation.</description><subject>Adult</subject><subject>Alcohol Oxidoreductases - analysis</subject><subject>Aldehyde Reductase</subject><subject>Aldo-Keto Reductases</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Biological Transport</subject><subject>Cell Line</subject><subject>Daunorubicin - metabolism</subject><subject>Daunorubicin - pharmacology</subject><subject>Drug Resistance</subject><subject>Drug Synergism</subject><subject>General aspects</subject><subject>Humans</subject><subject>Leukemia, Myeloid - metabolism</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Verapamil - pharmacology</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1986</creationdate><recordtype>article</recordtype><recordid>eNpFkE1Lw0AQhhdRaq1evAt78CREZzNJNzlqsSoUvOg5zH5EV5Js2d0c-u-NtNTLvAzvwww8jF0LuBcA8uFpDZAv81zKEzYXBeYZVAWesjlgUWSlhOKcXcT4AwCFQJyxGZZYY4VzplZ-SMGpMTk_cN9yE8YvngINcetD4jQYHqwZdaJoI0-eGxoHH0bltBumKrqYaNCWT9v32NPA-53tvN4lp7m2XRcv2VlLXbRXh1ywz_Xzx-o127y_vK0eN5lGIVJmZCsJllgKocAgSNRmGlAqQmuEAN2WmixJYUhUWFQEQlYgSUFdogJcsLv9XR18jMG2zTa4nsKuEdD8eWr-PU3wzR7ejqq35ogexEz97aGnqKlrJyHaxSMm63o5vcdfIKZwYQ</recordid><startdate>19860101</startdate><enddate>19860101</enddate><creator>VASANTHAKUMAR, G</creator><creator>AHMED, N. K</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19860101</creationdate><title>Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells</title><author>VASANTHAKUMAR, G ; AHMED, N. K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c311t-d7f7a063511b0d3073cd07305ba3ed110cf5caea71da18348a017807ab0953b03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1986</creationdate><topic>Adult</topic><topic>Alcohol Oxidoreductases - analysis</topic><topic>Aldehyde Reductase</topic><topic>Aldo-Keto Reductases</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Biological Transport</topic><topic>Cell Line</topic><topic>Daunorubicin - metabolism</topic><topic>Daunorubicin - pharmacology</topic><topic>Drug Resistance</topic><topic>Drug Synergism</topic><topic>General aspects</topic><topic>Humans</topic><topic>Leukemia, Myeloid - metabolism</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Verapamil - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VASANTHAKUMAR, G</creatorcontrib><creatorcontrib>AHMED, N. K</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VASANTHAKUMAR, G</au><au>AHMED, N. K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>1986-01-01</date><risdate>1986</risdate><volume>18</volume><issue>2</issue><spage>105</spage><epage>110</epage><pages>105-110</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>We developed three daunorubicin (D1)-resistant sublines (ML1/I, II, III) from the human myelocytic cell line (ML1). These sublines were 28-, 70- and 162-fold more resistant than sensitive (ML1/S) cells to the cytotoxicity of D1 and were cross-resistant to adriamycin, epiadriamycin, actinomycin D, VP-16, VM26, and mitoxantrone. Steady-state levels of D1 in resistant sublines I and II, in the presence or absence of azide, were not significantly different from those of sensitive cells. However, the steady-state level of D1 in subline III was significantly increased in the presence of sodium azide. D1 efflux was minimal in ML1/S and resistant cells in the absenced of glucose. Addition of glucose enhanced D1 efflux only in subline III. Verapamil increased the cellular levels of D1 and inhibited its efflux from resistant III cells but not from ML1/S cells. Verapamil also greatly enhanced the cytotoxicity of D1 for sublines I, II, and III. The differences between sensitive and resistant cells in D1 uptake and retention seemed inadequate to cause 162-fold resistance and suggested other factors may be contributing to the development of resistance. In support of this hypothesis, daunorubicin reductase activity was significantly lower in resistant cells than in ML1/S cells. The greatest decrease in activity occurred at pH 8.5 which represents aldehyde reductases. Currently, we are investigating other possibilities for D1 metabolism, such as aglycone and free radical formation.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>3539383</pmid><doi>10.1007/BF00262277</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0344-5704 |
ispartof | Cancer chemotherapy and pharmacology, 1986-01, Vol.18 (2), p.105-110 |
issn | 0344-5704 1432-0843 |
language | eng |
recordid | cdi_crossref_primary_10_1007_BF00262277 |
source | Springer Online Journal Archives (Through 1996) |
subjects | Adult Alcohol Oxidoreductases - analysis Aldehyde Reductase Aldo-Keto Reductases Antineoplastic agents Biological and medical sciences Biological Transport Cell Line Daunorubicin - metabolism Daunorubicin - pharmacology Drug Resistance Drug Synergism General aspects Humans Leukemia, Myeloid - metabolism Medical sciences Pharmacology. Drug treatments Verapamil - pharmacology |
title | Contribution of drug transport and reductases to daunorubicin resistance in human myelocytic cells |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T02%3A09%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Contribution%20of%20drug%20transport%20and%20reductases%20to%20daunorubicin%20resistance%20in%20human%20myelocytic%20cells&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=VASANTHAKUMAR,%20G&rft.date=1986-01-01&rft.volume=18&rft.issue=2&rft.spage=105&rft.epage=110&rft.pages=105-110&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/BF00262277&rft_dat=%3Cpubmed_cross%3E3539383%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c311t-d7f7a063511b0d3073cd07305ba3ed110cf5caea71da18348a017807ab0953b03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/3539383&rfr_iscdi=true |